Galena Biopharma Inc (GALE) EPS Estimated At $-0.15

November 7, 2017 - By Kurt Siggers

 Galena Biopharma Inc (GALE) EPS Estimated At $ 0.15

Analysts await Galena Biopharma Inc (NASDAQ:GALE) to report earnings on November, 8. They expect $-0.15 EPS, up 62.50 % or $0.25 from last year’s $-0.4 per share. After $-0.16 actual EPS reported by Galena Biopharma Inc for the previous quarter, Wall Street now forecasts -6.25 % EPS growth. About 36,982 shares traded. Galena Biopharma Inc (NASDAQ:GALE) has declined 98.04% since November 7, 2016 and is downtrending. It has underperformed by 114.74% the S&P500.

Galena Biopharma Inc (NASDAQ:GALE) Ratings Coverage

Among 7 analysts covering Galena Biopharma (NASDAQ:GALE), 3 have Buy rating, 0 Sell and 4 Hold. Therefore 43% are positive. Galena Biopharma has $6 highest and $2 lowest target. $4.40’s average target is 1391.53% above currents $0.295 stock price. Galena Biopharma had 16 analyst reports since August 7, 2015 according to SRatingsIntel. FBR Capital downgraded Galena Biopharma Inc (NASDAQ:GALE) rating on Monday, February 6. FBR Capital has “Mkt Perform” rating and $4 target. The firm has “Buy” rating by TH Capital given on Tuesday, November 10. The stock has “Sell” rating by Cantor Fitzgerald on Friday, August 7. As per Wednesday, August 12, the company rating was downgraded by Zacks. The rating was downgraded by Raymond James to “Market Perform” on Wednesday, June 29. The firm has “Outperform” rating given on Wednesday, September 9 by Raymond James. Maxim Group maintained Galena Biopharma Inc (NASDAQ:GALE) rating on Friday, December 2. Maxim Group has “Buy” rating and $4 target. The firm earned “Outperform” rating on Thursday, November 12 by Oppenheimer. The stock of Galena Biopharma Inc (NASDAQ:GALE) has “Outperform” rating given on Friday, July 22 by FBR Capital. The company was maintained on Tuesday, November 10 by Roth Capital.

Galena Biopharma, Inc. is a biopharmaceutical company. The company has market cap of $11.34 million. The Firm focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. It currently has negative earnings. The Company’s development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax , GALE-301 and GALE-302.

More notable recent Galena Biopharma Inc (NASDAQ:GALE) news were published by: Prnewswire.com which released: “SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of …” on October 31, 2017, also Globenewswire.com with their article: “Galena Biopharma Enters into Merger Agreement with SELLAS Life Sciences Group” published on August 08, 2017, Seekingalpha.com published: “Galena Biopharma (GALE) Discusses Galena Biopharma and SELLAS Life Sciences …” on August 11, 2017. More interesting news about Galena Biopharma Inc (NASDAQ:GALE) were released by: Seekingalpha.com and their article: “No Reasonable Path Forward For Galena Shareholders – Avoid” published on February 08, 2017 as well as Globenewswire.com‘s news article titled: “Galena Biopharma Board of Directors Appoints Stephen F. Ghiglieri as Interim …” with publication date: February 21, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.